DOCSLIB.ORG

Softgel Healthcare Private Limited - Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Softgel Healthcare Private Limited - Product List Softgel Healthcare Private Limited - Product List # Generic Name Label Claim Acetaminophen Each soft gelatin capsule contains: 325mg,Dextromethorphan Acetaminophen USP 325mg 1 Hydrobromide15mg with Dextromethorphan Hydrobromide BP 15mg Pseudoephedrine HCL30mg Capsules Pseudoephedrine Hydrochloride BP 30mg Each soft gelatin capsule contains: 2 Acetaminophen Capsules 500 mg Acetaminophen USP 500 mg Each soft gelatin capsule contains: 3 Acetaminophen Capsules 650 mg Acetaminophen USP 650 mg Each soft gelatin capsule contains: Acetaminophen 500 mg with Caffeine 4 Acetaminophen USP 500mg 25 mg Capsules Caffeine USP 25mg Each soft gelatin capsule contains: Acetaminophen 325 mg , Caffeine 30 Acetaminophen USP 325mg 5 mg with Ibuprofen 200 mg Capsules Caffeine USP 30mg Ibuprofen USP 200mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325mg 6 Hydrobromide with Chlorpheniramine Dextromethorphan Hydrobromide USP 15mg Maleate Capsules Chlorpheniramine Maleate USP 4mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325mg 7 Hydrobromide with Doxylamine Dextromethorphan Hydrobromide USP 10mg Succinate Capsules Doxylamine Succinate USP 6.25mg Each soft gelatin capsule contains: Acetaminophen, Dextromethorphan Acetaminophen USP 325 mg 8 Hydrobromide with Doxylamine Dextromethorphan Hydrobromide USP 15 mg Succinate Capsules Doxylamine Succinate USP 6.25 mg Each soft gelatin capsule contains: Acetaminophen, dextromethorphan HBr Acetaminophen USP 325mg 9 with phenylephrine Hcl Capsules Dextromethorphan Hydrobromide USP 10mg Phenylephrine Hydrochloride USP 5mg Each soft gelatin capsule contains: Acetaminophen, dextromethorphan HBr Acetaminophen USP 325 mg 10 with phenylephrine Hcl Capsules Dextromethorphan Hydrobromide USP 10 mg Phenylephrine Hydrochloride USP 5 mg Each soft gelatin capsule contains: Acetaminophen, dextromethorphan Acetaminophen USP 325mg 11 HBr, doxylamine succinate with Dextromethorphan Hydrobromide USP 15mg chlorpheniramine maleate Capsules Doxylamine Succinate USP 6.25mg Chlorpheniramine Maleate USP 4mg # Generic Name Label Claim Each soft gelatin capsule contains: 12 Alfacalcidol Capsules 0.25 mcg Alfacalcidol BP 0.25mcg Each soft gelatin capsule contains: 13 Alfacalcidol Capsules 0.5 mcg Alfacalcidol BP 0.5mcg Each soft gelatin capsule contains: 14 Alfacalcidol Capsules 1 mcg Alfacalcidol BP 1mcg Each soft gelatin capsule contains: Alfacalcidol BP 0.25mcg 15 Alfacalcidol with calcium Capsules Calcium carbonate IP 625mg equivalent to elemental calcium 250mg Each soft gelatin capsule contains: Alfacalcidol BP 0.25mcg 16 Alfacalcidol with calcium Capsules Elemental calcium 200mg (derived from calcium carbonate -Oyster shell) Each soft gelatin capsule contains: Alfacalcidol BP 0.25mcg 17 Alfacalcidol with calcium Capsules Calcium carbonate IP 500mg equivalent to elemental calcium 200mg Aloe vera extract (200 :1) Capsules 25 Each soft gelatin capsule contains: 18 mg Aloe Vera Extract (200:1) 25mg Each soft gelatin capsule contains: Alpha Lipoic acid 50mg Fish oil, Rich in omega-3-fatty acids BP containing, Eicosapentaenoic Acid (EPA) 45 mg Docosahexaenoic Acid (DHA) 30 mg Alpha lipoic acid with eicosapentaenoic Mixed Carotenoids-30% Oily Suspension 10 mg 19 acid, docosahexaenoic acid, lycopene Zinc (As Zinc Sulfate Monohydrate) USP 7.5 mg & antioxidant minerals Capsules Lycopene 10% USP 5 mg Manganese (As Manganese Sulfate Monohydrate) USP 1.5 mg Copper (As Cupric Sulfate) USP 1 mg Chromium (As Chromium Chloride Hexahydrate) USP 40 mcg Selenium (As Sodium Selenate) 150 mcg Each soft gelatin capsule contains: Cholecalciferol IP 1000 IU Pyridoxine 3mg 20 Alpha lipoic acid with vitamin Capsules Folic acid 1.5mg Methylcobalamin 1500mcg Alpha Lipoic acid USP 100mg # Generic Name Label Claim Each soft gelatin capsule contains: Alpha Lipoic acid 135 mg Alpha lipoic acid, chromium, zinc with 21 Zinc sulphate monohydrate Eq. to Zinc 38.7 mg methylcobalamin Capsules Methylcobalamin 180-mcg Chromium picolinate Eq. to chromium 180 mcg Each soft gelatin capsule contains: Methylcobalamin 1500 mcg GLA (as Borage oil BP) 60 mg Alpha lipoic acid, methylcobalamin, Alpha Lipoic acid USP 100 mg gamma linolenic acid, folic acid, 22 Folic acid BP 1.5 mg pyridoxine hydrochloride, biotin, Pyridoxine Hcl BP 3 mg chromium & zinc Capsules Biotin USP 3 mg Chromium (as Chromium Picolinate USP) 100 mcg Zinc (as Zinc sulphate monohydrate USP) 10 mg Each soft gelatin capsule contains: Methylcobalamin 750 mcg Alpha lipoic acid, methylcobalamin, Pregabalin 75 mg 23 pregabalin, folic acid & pyridoxine Folic Acid BP 1.5 mg hydrochloride Capsules Pyridoxine Hydrochloride BP 3 mg Alpha Lipoic Acid USP 100 mg Each soft gelatin capsule contains: 24 Alpha lipoic acid 300mg Capsules Alpha lipoic acid USP 300mg Each soft gelatin capsule contains: Vitamin A(as palmitate) BP 2500IU Thiamine Nitrate BP 1.0mg Riboflavin BP 1.0mg Pyridoxine hydrochloride BP 1.34 mg Cyanocobalamin BP 1.0mcg Cholecalciferol BP 200IU Calcium Pantothenate BP 1.0mg Nicotinamide BP 15mg Amino acids with multivitamin and 25 Calcium (From Anhydrous Calcium Hydrogen Phosphate BP) 50mg minerals Capsules Phosphorus(From Anhydrous Calcium Hydrogen Phosphate BP) 38.75mg Copper( from Anhydrous Copper Sulphate BP)0.01mg Magnesium(from Dried Magnesium Sulphate BP)0.5 mg Manganese (from Manganese Sulphate BP) 0.01mg Potassium (from Potassium Sulphate BP)1mg Zinc (from Zinc Sulphate Monohydrate BP) 0.15mg Lysine Hydrochloride BP 25mg Glutamic Acid BP100mg # Generic Name Label Claim Each soft gelatin Capsules contains: Arginine Hydrochloride BP 13.28 mg Histidine Hydrochloride Monohydrate BP 3.71 mg Leucine BP 18.3 mg Isoleucine BP 5.9 mg Lysine Hydrochloride BP 25.0mg Phenylalanine BP 5.0mg Threonine BP 4.2mg Valine BP 6.7mg Tryptophan BP 5.0mg DL- Methionine BP 18.4mg 5 hydroxyanthranilic acid 0.2mg Amino acids with multivitamin, minerals 26 Vitamin A ( As palmitate) BP 2500IU and selenium Capsules Cholecalciferol BP 200IU Thiamine nitrate BP 5.0mg Riboflavin BP 3.0mg Nicotinamide BP 25.0mg Pyridoxine Hydrochloride BP 1.5mg Folic acid BP 0.75mg Calcium Pantothenate BP 5.0mg Cyanocobalamin BP 2.5mcg Ascorbic acid BP 40.0mg all-rac -Alpha-Tocopheryl Acetate BP 7.5IU Zinc sulfate USP 50.0mg Selenium (as Selenomethionine) USP 35.0mcg Each soft gelatin capsule contains: L -Leucine 18.3 mg L-Isoleucine 5.9 mg L-Lysine Hcl25 mg L-phenylalanine 5 mg L- threonine 4.2 mg L- valine 6.7 mg L-Tryptophan 5 mg Dl methionine 18.4 mg 5 Hydroxyanthranilic acid 0.2 mg 27 Amino acids with vitamins Vitamin A 2500 IU Cholecalciferol 200 IU Thiamine mononitrate 5 mg Riboflavin 3 mg Nicotinamide 25 mg Pyridoxine HCL1.5 mg Folic acid 0.75 mg Calcium Pantothenate 5 mg Cyanocobalamin 2.5 mcg (as 1%) 250 mcg Ascorbic acid 40 mg Tocopheryl acetate 7.5 IU # Generic Name Label Claim Each soft gelatin capsule contains: Vitamin A as palmitate BP 800 mcg Vitamin D3 (cholecalciferol) BP 10 mcg Vitamin E (d alpha tocopheryl acetate) USP 40 mg Beta carotene (natural carotenoids 30%) BP 3 mg Vitamin B3 (Nicotinamide) BP 27 mg Pantothenic acid (as Calcium Pantothenate BP) 20 mg Vitamin C (Calcium Ascorbate) BP 150 mg Vitamin B1 (Thiamin mononitrate) USP 18 mg Vitamin B2 (Riboflavin) BP 6 mg Vitamin B9 (Folic acid) BP 500 mcg Vitamin B12 (Cyanocobalamin) BP 14 mcg Aminoacids, Multivitamin with minerals 28 Vitamin B6 (Pyridoxine hydrochloride) BP 10mg Capsules Vitamin K3 (Menadione) BP 70 mcg Zinc (as Zinc sulphate monohydrate BP) 15 mg Iron (as Ferrous Fumarate BP) 8 mg Iodine (as Potassium iodide BP) 200 mcg Magnesium (as Magnesium oxide BP) 50 mg Copper ( as copper sulphate pentahydrate BP) 500 mcg Manganese (as Manganese sulphate monohydrate BP) 4 mg Chromium (Chromium trichloride) 100 mcg L-cystine BP 40 mg L-carnitine 30 mg Citrus and grape skin Bioflavonoids 30 mg Selenium (as Sodium selenite) 180 mcg Each soft gelatin capsule contains: 29 Ascorbic acid chewable Capsules Ascorbic acid 125 mg Each soft gelatin capsule contains: Ashwagandha 200mg + Swet Musli Nigella Sativa 100mg 30 200mg + Black Seed Oil 75 mg Ashwagandha (Withania Somnifera) 200mg Capsules Swet Musli (Asparagus Adscendens) 200mg Tribulus (Tribulus Terrestris) 200mg Each soft gelatin capsule contains: Benfotiamine150 mg Benfothiamine, methylcobalamin, alpha Methylcobalamin JP1500 mcg lipoic acid, inositol, folic acid, chromium Alpha Lipoic acid USP200 mg 31 polynicotinate and pyridoxine Inositol 100 mg hydrochloride Capsules Folic acid IP1.5 mg Chromium Polynicotinate200 mcg Pyridoxine Hydrochloride IP3 mg # Generic Name Label Claim Each soft gelatin capsule contains: Methylcobalamin 750mcg Alpha Lipoic Acid USP 100mg Benfothiamine 75mg Benfothiamine, Methylcobalamin, Folic Acid IP 500mcg 32 vitamin with minerals Capsules Pyridoxine Hydrochloride IP 1.5mg Inositol BP 500mg Sodium Selenite Pentahydrate BP 30mcg Calcium D - Pantothenate IP 2.5mg Vitamin E 2.5mg Each soft gelatin capsule contains: Natural beta Carotene 4000 IU Lutein Esters 6mg Folic acid 2.5 mg Cyanocobalamin 500 mcg Beta carotene, lutein, vitamins and 33 Pyridoxine Hcl50 mg minerals soft gelatin Capsules Manganese as manganese sulphate mono 1.5 mg Copper (as copper sulphate pentahydrate) 2 mg Selenium (as selenium dioxide) 75 mcg Zinc (as zinc sulphate monohydrate) 15 mg Chromium (as chromium picolinate) 50 mcg Each soft gelatin Capsules contains: Methylcobalamin 500mcg Beta carotene 15% BP 10.33mg Beta carotenoids, alpha lipoic acid, Alpha Lipoic acid USP 100mg 34 methylcobalamin, vitamins and minerals Thiamine nitrate BP 2.5mg
Load more

Recommended publications
  • Daily Lifestyle Modifications to Improve Quality of Life And
    brain sciences Review Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review Sarah Travers and N. Scott Litofsky * Division of Neurosurgery, University of Missouri School of Medicine, Columbia, MO 65212, USA; [email protected] * Correspondence: [email protected] Abstract: Survival in glioblastoma remains poor despite advancements in standard-of-care treatment. Some patients wish to take a more active role in their cancer treatment by adopting daily lifestyle changes to improve their quality of life or overall survival. We review the available literature through PubMed and Google Scholar to identify laboratory animal studies, human studies, and ongoing clinical trials. We discuss which health habits patients adopt and which have the most promise in glioblastoma. While results of clinical trials available on these topics are limited, dietary restrictions, exercise, use of supplements and cannabis, and smoking cessation all show some benefit in the comprehensive treatment of glioblastoma. Marital status also has an impact on survival. Further clinical trials combining standard treatments with lifestyle modifications are necessary to quantify their survival advantages. Keywords: survival in glioblastoma; dietary restriction in glioblastoma; cannabis use in glioblastoma; supplementation in glioblastoma; glioblastoma health modifications Citation: Travers, S.; Litofsky, N.S. Daily Lifestyle Modifications to 1. Introduction Improve Quality of Life and Survival Glioblastoma remains the most aggressive and deadly form of primary brain tumor, in Glioblastoma: A Review. Brain Sci. with average survival rates ranging from 7.8 to 23.4 months after diagnosis [1]. Maximal 2021, 11, 533. https://doi.org/ surgical resection followed by radiation and temozolomide have become standard of 10.3390/brainsci11050533 care [2,3].
    [Show full text]
  • Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information
    healthcare Review Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information Aleksandra Podgórska †, Anna Pu´scion-Jakubik*,† , Renata Markiewicz-Zukowska˙ , Krystyna Joanna Gromkowska-K˛epkaand Katarzyna Socha Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland; [email protected] (A.P.); [email protected] (R.M.-Z.);˙ [email protected] (K.J.G.-K.); [email protected] (K.S.) * Correspondence: [email protected]; Tel.: +48-8574-854-69 † Contributed equally. Abstract: Acne vulgaris (AV) is a chronic disease that affects a significant percentage of the world’s population. Its development is influenced by both external and internal factors. The purpose of this review is to demonstrate the effect of basic nutrient intake on the exacerbation or alleviation of AV lesions. A retrospective review of publications in PubMed regarding diet therapy and the impact of individual nutrient intake on the skin condition of patients was conducted. Ingestion of products with a high glycaemic index may indirectly lead to sebum overproduction, which promotes infection with Cutibacterium acnes and causes inflammation. Consumption of certain dairy products may result Citation: Podgórska, A.; in skin deterioration caused by the presence of hormones in these products, i.e., progesterone and Pu´scion-Jakubik,A.; testosterone precursors. The beneficial effect of fatty acids on the skin is manifested by the reduction Markiewicz-Zukowska,˙ R.; Gromkowska-K˛epka,K.J.; Socha, K. in inflammation. Of significance in AV treatment are vitamins A, C, D, E and B, as well as mineral Acne Vulgaris and Intake of Selected elements zinc and selenium.
    [Show full text]
  • Vitamin D and Its Analogues Decrease Amyloid- (A) Formation
    International Journal of Molecular Sciences Article Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation Marcus O. W. Grimm 1,2,3,*,† ID , Andrea Thiel 1,† ID , Anna A. Lauer 1 ID , Jakob Winkler 1, Johannes Lehmann 1,4, Liesa Regner 1, Christopher Nelke 1, Daniel Janitschke 1,Céline Benoist 1, Olga Streidenberger 1, Hannah Stötzel 1, Kristina Endres 5, Christian Herr 6 ID , Christoph Beisswenger 6, Heike S. Grimm 1 ID , Robert Bals 6, Frank Lammert 4 and Tobias Hartmann 1,2,3 1 Experimental Neurology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany; [email protected] (A.T.); [email protected] (A.A.L.); [email protected] (J.W.); [email protected] (J.L.); [email protected] (L.R.); [email protected] (C.N.); [email protected] (D.J.); [email protected] (C.B.); [email protected] (O.S.); [email protected] (H.S.); [email protected] (H.S.G.); [email protected] (T.H.) 2 Neurodegeneration and Neurobiology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 3 Deutsches Institut für DemenzPrävention (DIDP), Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 4 Department of Internal Medicine II–Gastroenterology, Saarland University Hospital, Saarland University, Kirrberger Str. 100, 66421 Homburg/Saar, Germany; [email protected] 5 Department of Psychiatry and Psychotherapy, Clinical Research Group, University Medical Centre Johannes Gutenberg, University of Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany; [email protected] 6 Department of Internal Medicine V–Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Str.
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Vitamin D to Prevent Exacerbations of COPD: Systematic Review and Meta- Analysis of Individual Participant Data from Randomised Controlled Trials
    Vitamin D to prevent exacerbations of COPD: systematic review and meta- analysis of individual participant data from randomised controlled trials APPENDIX Search Strategies A. PubMed Cochrane Highly Sensitive Search Strategy for identifying randomized controlled trials #1. randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab] #2. animals [mh] NOT humans [mh] #3. #1 NOT #2 Terms specific to vitamin D #4. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol Terms specific to chronic obstructive pulmonary disease #5 COPD OR chronic obstructive pulmonary disease OR emphysema Combination of terms to identify randomized controlled trials of vitamin D conducted in patients with asthma #3 AND #4 AND #5 B. EMBASE Terms for identifying randomized controlled trials #1 ‘randomized controlled trial’/exp OR ‘single blind procedure’/exp OR ‘double blind procedure’/exp OR ’crossover procedure’/exp #2 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEXT/1 blind*):ab,ti OR trial:ti #3. #1 OR #2 1 Terms specific to vitamin D #4. vitamin AND d OR vitamin AND d2 OR vitamin AND d3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol Terms specific to chronic obstructive pulmonary disease #5. Chronic Obstructive Pulmonary Disease OR COPD OR COAD OR emphysema OR chronic bronchitis OR AECB OR AECOPD Combination of terms to identify randomized controlled trials of vitamin D conducted in patients with chronic obstructive pulmonary disease #3 AND #4 AND #5 C.
    [Show full text]
  • Vitamin D and Cancer
    WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER Vitamin D and Cancer IARC 2008 WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Working Group Reports Volume 5 Vitamin D and Cancer - i - Vitamin D and Cancer Published by the International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France © International Agency for Research on Cancer, 2008-11-24 Distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]) Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturer’s products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The authors alone are responsible for the views expressed in this publication. The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its publications, in part or in full.
    [Show full text]
  • Nutrition and Blood
    Greater Manchester Joint Formulary Chapter 9: Nutrition and Blood For cost information please go to the most recent cost comparison charts Contents 9.1. Anaemias and some other blood disorders 9.2 Fluids and electrolytes 9.3 Not listed 9.4. Oral nutrition 9.5 Minerals 9.6 Vitamins Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents Chapter 9 – page 1 of 16 V5.2 Greater Manchester Joint Formulary BNF chapter 9 Nutrition and Blood Section 9.1. Anaemias and some other blood disorders Subsection 9.1.1 Iron-deficiency anaemias Subsection 9.1.1.1 Oral iron First choice Ferrous fumarate 322 mg tabs (100 mg iron) Ferrous fumarate 305 mg caps (100 mg iron) Alternatives Ferrous fumarate 210 mg tabs (68 mg iron) Ferrous sulphate 200 mg tabs (65 mg iron) Ferrous fumarate 140 mg sugar free syrup (45 mg of iron/5 mL) Sodium feredetate 190 mg sugar free elixir (27.5 mg of iron/5 mL) Grey drugs Ferric maltol capsules Items which Criterion 2 (see RAG list) are listed as For treatment of iron deficiency anaemia in patients with Grey are intolerance to, or treatment failure with, two oral iron deemed not supplements.
    [Show full text]
  • Blood and Electrolyte Disorders, and Vitamin Deficiencies
    Medicines Formulary Blood and electrolyte disorders, and vitamin deficiencies Contents: Blood disorders 1 1. Anaemia 2 A. Non-renal patients 2 B. Patients with chronic kidney disease under the care of a nephrologist 3 2. Megaloblastic anaemia 4 3. Secondary hyperparathyroidism 4 Electrolyte disorders 5 4. Hypokalaemia 5 5. Hyperkalaemia 7 6. Hyponatraemia 8 7. Hypernatraemia 9 8. Hypocalcaemia 9 9. Hypomagnesaemia 10 10. Hypophosphataemia 11 11. Hyperphosphataemia 12 12. Hyperaluminaemia 13 Vitamin deficiencies 13 13. Vitamin D deficiency 14 14. Vitamin K deficiency 16 For full information on treatment side effects, cautions and contraindications, see electronic British National Formulary (www.bnf.org) or the relevant summary of product characteristics (www.medicines.org.uk). For information on preparing intravenous medicines for administration, see Medusa Injectable Medicines Guide for the NHS (see Clinical Guidance home page) Nutrition Blood disord ers Blood and electrolyte disorders, and vitamin deficiencies — Medicines Formulary, v8 Author: Gareth Malson Approved by Medicines Clinical Guidance Team: May 2013 Review by: May 2016 Page 1 of 16 1. Anaemia A. Non-renal patients When treating anaemia, a patient’s haemoglobin concentration should increase by 10g/L each week. Therapy should be continued for 3 months after the haemoglobin levels have normalised to replenish the body’s iron stores. Options for treatment include: i) Oral iron ii) Parenteral iron i) Oral iron First choice in secondary care Ferrous sulphate 200mg (60mg elemental
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Dialyzability of Medications During Intermittent Hemodialysis
    DialyzeIHD: Dialyzability of Medications During Intermittent Hemodialysis % Dialyzed % Dialyzed % Dialyzed % Dialyzed IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration Timing Drug (Type of Drug (Type of Drug (Type of Drug (Type of Timing Around HD Session Timing Around HD Session Around HD Session Dialyzer) Timing Around HD Session Dialyzer) Dialyzer) Dialyzer) 0.25-0.5mg PO Q8H PRN, Insulin Aspart, Pentamidine 0 4mg/kg IV Q24-36H, Not recommended for use, Clonazepam N/A Reduce to 25-50% of normal dose Acarbose N/A Administer anytime during HD Insulin Detemir, Isethionate (N/A) Administer anytime during HD Administer anytime during HD N/A and titrate, Administer anytime Insulin Glargine, 0.1-0.4mg PO Q8-12H, during HD Normal dose and titrate based on 100-150mg PO Q12-24H, <5 Insulin Lispro Acebutolol N/A Clonidine Administer anytime during HD; No target free or corrected total Administer post-HD (Low Flux) Phenytoin Dose post-HD if hypotensive 75-300mg PO Q24H, (Low Flux) phenytoin level, Normal dose based on indication, 0 Administer anytime during HD Acetaminophen N/A 75mg PO Q24H, Irbesartan Administer anytime during HD; Dose Administer anytime during HD Clopidogrel N/A (N/A) Administer anytime during HD post-HD if hypotensive No 15-45mg PO Q24H, Pioglitazone 2.5-5mg/kg IV/PO Q24H, (N/A) Administer anytime during HD 40-60 250-500mg PO Q6H or 1-2g IV Q4- 100mg IV weekly to monthly, Acyclovir Administer post-HD over 60 Cloxacillin N/A Iron Dextran N/A (N/A) 6H, Administer anytime
    [Show full text]